Listed by the USPTO as FONSECA LOPEZ, FRANCINI ALVARENGA
Tech Center 1600 • Art Units: 1635 1645 1682 1685
This examiner grants 27% of resolved cases
FONSECA LOPEZ, FRANCINI ALVARENGA is assigned to Tech Center 1600 and art unit 1635. The profile includes 33 resolved cases, an allowance rate of 27.3%, an interview lift of 32.6%, and a median of 1552 days to allowance. The case volume is limited, but the figures identify interview activity and a recorded prosecution timeline for examiner-specific planning.
The companies listed are DeepMind Technologies Limited, Fujifilm Holdings Corporation, and Canon Inc. The firms are Alford Law Group, Inc., Barclay Damon, LLP, and Bridgeway IP Law Group, PLLC. Counsel can use these entries to locate prior matters and assess possible procedural context. Decisions about claim scope, amendments, and interview use should remain tied to the particular application history.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18058110 | PREDICTION OF PEPTIDE CLEAVAGE IN POLYPEPTIDES THROUGH PHYSICS-BASED SIMULATIONS | Final Rejection | Genentech, Inc. |
| 18412092 | QUALITY MANAGEMENT METHOD FOR SPECIFIC CELL AND METHOD OF PRODUCING SPECIFIC CELL | Non-Final OA | FUJIFILM Corporation |
| 18498968 | ANALYSIS APPARATUS | Non-Final OA | Canon Kabushiki Kaisha |
| 18372565 | METHODS FOR ALLELE CALLING AND PLOIDY CALLING | Non-Final OA | Natera, Inc. |
| 18191723 | RNA SCAFFOLDED WIREFRAME ORIGAMI AND METHODS THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 17414480 | METHODS FOR IDENTIFYING NEOANTIGENS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 19340736 | PLATFORMS, SYSTEMS, AND METHODS FOR MULTI-OBJECTIVE OPTIMIZATION AND COMPARATIVE ANALYSIS FOR SYNTHETIC BIOLOGY DEVELOPMENT | Non-Final OA | X Development LLC |
| 17872823 | DIABETES PREDICTION USING GLUCOSE MEASUREMENTS AND MACHINE LEARNING | Final Rejection | DexCom, Inc. |
| 17553295 | System and Method for Control of Sequencing Process | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 17780037 | METHOD AND SYSTEM USING INTEGRATIVE MULTI-OMIC DATA ANALYSIS FOR EVALUATING THE FUNCTIONAL IMPACTS OF GENOMIC VARIANTS | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 18224308 | METHOD AND APPARATUS FOR PROVIDING A PHARMACOKINETIC DRUG DOSING REGIMEN | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18026058 | METHODS AND COMPOSITIONS FOR PROGNOSING GLIOBLASTOMA OR BREAST CANCER | Final Rejection | The Johns Hopkins University |
| 17806075 | TRANSFORMER-BASED GRAPH NEURAL NETWORK TRAINED WITH STRUCTURAL INFORMATION ENCODING | Non-Final OA | Microsoft Technology Licensing, LLC |
| 17435852 | QUANTITATION OF SECONDARY DEGRADATION IN UNAFFECTED JOINTS RESULTING FROM OSTEOARTHRITIS OF THE KNEE OR HIP | Non-Final OA | Smith & Nephew Orthopaedics AG |
| 17795465 | DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINE LEVELS | Final Rejection | The Cleveland Clinic Foundation |
| 17924948 | SYSTEMS AND METHODS FOR DETECTING GENOME EDITS | Final Rejection | MONSANTO TECHNOLOGY LLC |
| 18443879 | EARLY DETECTION AND INTERVENTION OF AT-RISK SUBJECTS FOR PRODROMAL PARKINSON'S DISEASE | Non-Final OA | The Chinese University of Hong Kong |
| 18179144 | METHODS FOR CELL LABEL CLASSIFICATION | Non-Final OA | Becton, Dickinson And Company |
| 18182846 | RISK STRATIFICATION METHOD FOR THE DETECTION OF CANCERS IN PRECANCEROUS TISSUES | Non-Final OA | The Curators of the University of Missouri |
| 18025603 | METHODS AND SYSTEMS FOR SEQUENCE AND VARIANT CALLING | Non-Final OA | Ultima Genomics, Inc. |
| 18347691 | APPARATUS AND METHOD FOR SELECTING CATHODE MATERIAL FOR SODIUM-ION BATTERY USING MACHINE LEARNING | Non-Final OA | FOUNDATION OF SOONGSIL UNIVERSITY-INDUSTRY COOPERATION |
| 18027571 | PREDICTING SYMMETRICAL PROTEIN STRUCTURES USING SYMMETRICAL EXPANSION TRANSFORMATIONS | Non-Final OA | DeepMind Technologies Limited |
| 17849269 | DETERMINING A DISTRIBUTION OF ATOM COORDINATES OF A MACROMOLECULE FROM IMAGES USING AUTO-ENCODERS | Final Rejection | DeepMind Technologies Limited |
| 18042285 | IDENTIFYING A TARGET NUCLEIC ACID | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 17876528 | BASE CALLING USING MULTIPLE BASE CALLER MODELS | Final Rejection | ILLUMINA, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy27.3% of resolved applications examined by Francini Alvarenga Fonseca Lopez were allowed (33 resolved cases), compared with 51.3% across Art Unit 1635 over the last five years.
This examiner's interview lift is +32.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Francini Alvarenga Fonseca Lopez took 1,552 days on average from filing to allowance.
Francini Alvarenga Fonseca Lopez examines applications in Art Unit 1635 in Tech Center 1600 (Biotechnology & Pharmaceuticals).